Page last updated: 2024-12-06

artemotil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

artemotil: structure given in first source; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3000469
CHEMBL ID301267
CHEBI ID135335
SCHEMBL ID17156474
MeSH IDM0155369
PubMed CID72416
CHEMBL ID3560584
SCHEMBL ID1648554
MeSH IDM0155369

Synonyms (64)

Synonym
e mal
artecef
sm-227
artemotil
nsc-665971
(3r,5as,6r,8as,9r,10s,12r,12ar)-10-ethoxydecahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin
75887-54-6
arteether
beta-arteether
CHEBI:135335
CHEMBL301267
artemotilum
.beta.-arteether
S3889
xgl7gfb9yi ,
beta-dihydroartemisinin ethyl ether
bdbm50426305
AKOS022185297
SCHEMBL17156474
CS-5561
HY-B0770
alpha,beta arteether
(+)-arteether
b-arteether
(1r,4s,5r,8s,9r,10s,12r,13r)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
mfcd00869355
(3r,5as,6r,8as,9r,10s,12r,12ar)-10-ethoxy-3,6,9-trimethyldecahydro-3h-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene
DB13851
AS-15038
BCP28298
gtpl9958
CCG-267602
EN300-19768153
(1r,4s,5r,8s,9r,10s,12r,13r)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
.beta.-arteether [who-ip]
artemotilum [who-ip latin]
arteether [mi]
artemotil [who-ip]
arteether [who-ip]
artemotil [who-dd]
artemotil [mart.]
3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin, 10-ethoxydecahydro-3,6,9-trimethyl-, (3s-(3alpha,5alpha,6alpha,8aalpha,9beta,10beta,12beta,12aalpha))-
sm 227
3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-ethoxy-3,6,9-trimethyl-, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12ar*))-
artemotil (inn)
D07361
3,12-epoxy-12h-pyrano[4,3-j]-1,2-benzodioxepin, 10-ethoxydecahydro-3,6,9-trimethyl-, (3r,5as,6r,8as,9r,10s,12r,12ar)-
dihydroartemisinin ethyl ether
ethyl-ether-quinghaosu
wr-255131
artemotil [inn]
nsc 665971
unii-xgl7gfb9yi
cas-75887-54-6
dtxcid7031610
tox21_113883
NCGC00253770-01
dtxsid6057821 ,
SCHEMBL1648554
CHEMBL3560584
NLYNIRQVMRLPIQ-BVCZABNKSA-N
beta arteether
A915244
(3r,12ar)-3,6alpha,9beta-trimethyl-10beta-ethoxy-3beta,12alpha-epoxy-3,4,5,5aalpha,6,7,8,8aalpha,9,10-decahydropyrano[4,3-j]-1,2-benzodioxepin

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This selective uptake may explain why the artemisinin derivatives are selectively toxic to malaria parasites."( Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro.
Hossler, P; Kamchonwongpaisan, S; McKeever, P; Meshnick, SR; Ziffer, H, 1997
)
0.3
" In this assay, dihydroartemisinin is significantly more toxic than artemether or arteether."( In vitro neurotoxicity of artemisinin derivatives.
McLean, WG; Ward, SA, 1998
)
0.3
" Dihydroartemisinin (DQHS), a more toxic and active metabolite of AE, was also analyzed."( Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents.
Gettayacamin, M; Kyle, DE; Li, QG; Milhous, WK; Mog, SR; Si, YZ, 2002
)
0.31
" Both arteether formulations were safe and efficacious in reducing the clinical symptoms of acute falciparum malaria."( Efficacy and safety of beta-arteether and alpha/beta-arteether for treatment of acute Plasmodium falciparum malaria.
Kochar, D; Mathur, PC; Mishra, SK; Nandy, A; Pareek, A; Patel, KH, 2006
)
0.33
" Large clinical studies and meta-analyses did not show serious side effects, although proper monitoring of adverse effects in developing countries might not be a trivial task."( Toxicity of the antimalarial artemisinin and its dervatives.
Efferth, T; Kaina, B, 2010
)
0.36
"5 mg/kg for 7-28 days, indicating that the safe dosing duration in monkeys should be longer than 7 days under the exposure."( Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins.
Hickman, M; Li, Q, 2011
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
" Preliminary pharmacokinetic data showed a long elimination half life of 25-72 h and marked accumulation in the multiple dose study."( Arteether administration in humans: preliminary studies of pharmacokinetics, safety and tolerance.
Kager, PA; Schultz, MJ; van Boxtel, CJ; van den Berg, B; Zijlstra, EE, 1994
)
0.29
" The resulting pharmacokinetic parameter estimates were substantially different not only between drugs but also between routes of administration for the same drug."( The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats.
Brewer, TG; Fleckenstein, LL; Heiffer, MH; Li, QG; Masonic, K; Peggins, JO, 1998
)
0.3
" Cmax values of 63."( Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria.
Chalearmrult, K; Krudsood, S; Li, Q; Looareesuwan, S; Lugt, CB; Milhous, WK; Vannaphan, S; Wilairatana, P, 2004
)
0.32
" The beta-isomer of arteether was characterized by a longer elimination half-life and a relatively larger volume of distribution than the alpha-isomer, suggesting that beta-arteether may be responsible for the prolonged in vivo schizontocidal activity."( Pharmacokinetics of the diastereomers of arteether, a potent antimalarial drug, in rats.
Gupta, RC; Madhusudanan, KP; Sabarinath, S, 2005
)
0.33
"The study was a single-centre clinical pharmacokinetic trial in healthy male subjects."( Clinical pharmacokinetics of the diastereomers of arteether in healthy volunteers.
Asthana, OP; Gupta, RC; Madhusudanan, KP; Puri, SK; Sabarinath, SN; Srivastava, K, 2005
)
0.33
" Plasma carbamazepine levels were assayed by high-performance liquid chromatography and pharmacokinetic parameters calculated."( Effects of artemisinin, artemether, arteether on the pharmacokinetics of carbamazepine.
Medhi, B; Pandhi, P; Sukhija, M, 2006
)
0.33
" Plasma phenytoin levels were assayed by HPLC, and pharmacokinetic parameters were calculated."( Effects of artemisinin, artemether, and arteether on the pharmacokinetics of phenytoin.
Medhi, B; Pandhi, P; Sukhija, M, 2006
)
0.33
"The study was intended to investigate the effect of concomitant administration of antimalarial drug (pyrimethamine or arteether) on pharmacokinetic and post coitus contraceptive efficacy of ormeloxifene in female Sprague-Dawley rats."( Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene.
Jaiswal, S; Lal, J; Sharma, A; Shukla, M, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
" Antimalarial activity of curcuminoids-loaded liposomes alone and in combination with α/β arteether when administered intravenously, was evaluated in Plasmodium berghei infected mice."( Curcuminoids-loaded liposomes in combination with arteether protects against Plasmodium berghei infection in mice.
Aditya, NP; Banerjee, R; Chimote, G; Gunalan, K; Madhusudhan, B; Patankar, S, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The pharmacokinetics and bioavailability of dihydroartemisinin (DQHS), artemether (AM), arteether (AE), artesunic acid (AS) and artelinic acid (AL) have been investigated in rats after single intravenous, intramuscular and intragastric doses of 10 mg kg(-1)."( The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats.
Brewer, TG; Fleckenstein, LL; Heiffer, MH; Li, QG; Masonic, K; Peggins, JO, 1998
)
0.3
"92 microg x h/ml) due to a higher bioavailability of AECM (74."( Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents.
Gettayacamin, M; Kyle, DE; Li, QG; Milhous, WK; Mog, SR; Si, YZ, 2002
)
0.31
" Pharmacokinetic studies indicated that low oral bioavailability due to poor ADME properties."( Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents.
Gupta, S; Kancharla, P; Khaliq, T; Korthikunta, V; Kumar, V; Mohammad, IS; Puri, SK; Raju, KS; Sijwali, PS; Soni, A; Srivastava, K; Srivastava, RK; Tadigoppula, N, 2013
)
0.39
" The % relative bioavailability (RB%) of ART-SLN to the ART in GNO and ART in aqueous suspension in rats was 169."( Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats.
Dwivedi, AK; Dwivedi, P; Khandelwal, K; Khatik, R; Mishra, PR; Paliwal, SK; Raju, KS; Taneja, I, 2014
)
0.4
" The pharmacokinetic study showed significantly enhanced bioavailability of ART in ART-NE-V."( Arteether nanoemulsion for enhanced efficacy against Plasmodium yoelii nigeriensis malaria: an approach by enhanced bioavailability.
Chaturvedi, P; Dwivedi, AK; Dwivedi, H; Dwivedi, P; Gupta, PK; Khandelwal, K; Khatik, R; Mishra, PR; Paliwal, SK; Raju, KS; Shukla, P; Singh, S; Singh, SK; Taneja, I; Tripathi, P; Tripathi, R, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" We noted a progressive syndrome of clinical neurological defects with cardio-respiratory collapse and death in 5/6 dogs dosed daily for 8 d with intramuscular arteether (AE) at 20 mg/kg/d in a pharmacokinetic study."( Neurotoxicity in animals due to arteether and artemether.
Brewer, TG; Grate, SJ; Heiffer, MH; Levine, BS; Peggins, JO; Petras, JM; Schuster, BG; Swearengen, J; Weina, PJ, 1994
)
0.29
" Patients were hospitalized and treated with a new ethyl derivative of artemisinin developed at CDRI called alpha, beta-arteether, at the dosage of 150 mg l/M for three consecutive days."( Efficacy of alpha,beta-arteether in acute uncomplicated P. falciparum malaria.
Adak, T; Asthana, OP; Biswas, S; Gupta, S; Sharma, A; Sharma, VP; Usha, D; Valecha, N, 1997
)
0.3
" Plasma was separated from blood samples collected at different times after dosing and analysed for parent drug."( The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats.
Brewer, TG; Fleckenstein, LL; Heiffer, MH; Li, QG; Masonic, K; Peggins, JO, 1998
)
0.3
" Animals were administered ARTE in sesame oil for 7 days, blood samples were collected using destructive sampling for up to 192 h after dosing and assayed by HPLC-ECD."( Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses.
Brewer, TG; Brueckner, RP; Li, QG; Peggins, JO; Trotman, KM,
)
0.13
"7 hours on day 4 for both dosage regimens."( Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria.
Chalearmrult, K; Krudsood, S; Li, Q; Looareesuwan, S; Lugt, CB; Milhous, WK; Vannaphan, S; Wilairatana, P, 2004
)
0.32
" Pharmacodynamic parameters such as area under the inhibitory curve, ratio of area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC), maximum plasma concentration to MIC (Cmax/MIC) and time that plasma concentration exceeds the MIC (T>MIC) were calculated in vitro in four strains of Plasmodium falciparum to evaluate the in vivo effectiveness of the proposed dosage regimen."( Clinical pharmacokinetics of the diastereomers of arteether in healthy volunteers.
Asthana, OP; Gupta, RC; Madhusudanan, KP; Puri, SK; Sabarinath, SN; Srivastava, K, 2005
)
0.33
"5 mg/kg for 7-28 days, indicating that the safe dosing duration in monkeys should be longer than 7 days under the exposure."( Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins.
Hickman, M; Li, Q, 2011
)
0.37
"Arteether monotherapy resulted in spontaneous fetal abortion or resorption, while dosage optimization and garlic combination resulted in pregnancy completion and malaria protection."( Promising New Antimalarial Combination Drugs: Garlic and Arteether in Pregnant Mice Infected with Plasmodium berghei.
Govindan, VP; Purushothama, KM, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
artemisinin derivativeAny organic peroxide formally obtained from artemisinin.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Artemisinin and Derivatives Pathway, Pharmacokinetics62

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.52310.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency9.43920.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency11.01340.000221.22318,912.5098AID1259243; AID1259247
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency6.51270.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
retinoid X nuclear receptor alphaHomo sapiens (human)Potency9.52050.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.59340.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
GVesicular stomatitis virusPotency15.48710.01238.964839.8107AID1645842
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency23.56800.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency1.55560.039147.5451146.8240AID1224845
Interferon betaHomo sapiens (human)Potency15.48710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (180)

Assay IDTitleYearJournalArticle
AID493715Antimalarial activity against multi drug-resistant Plasmodium yoelii nigeriensis infected in Swiss mice (Mus musculus) assessed as protection of patent infection at 48 mg/kg, perorally daily for 4 days measured after 28 days2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
6-(4'-Aryloxy-phenyl)vinyl-1,2,4-trioxanes: a new series of orally active peroxides effective against multidrug-resistant Plasmodium yoelii in Swiss mice.
AID19482Partition coefficient (logP)1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Synthesis, characterization, and antimalarial activity of the glucuronides of the hydroxylated metabolites of arteether.
AID119886In vivo antimalarial activity against Plasmodium yoelii in mice (Mus musculus) at 24 mg/kg/day orally on day 4 expressed as percent suppression2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Orally active amino functionalized antimalarial 1,2,4-trioxanes.
AID277701Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria.
AID158664Blood schizonticidal activity against Plasmodium berghei RC 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID661149Lipophilicity, log P of the compound2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID158798Blood schizonticidal activity against Plasmodium berghei ART1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID157680In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D72002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid.
AID256133Prophylactic activity in infected mouse at 40 mg/kg peroral administration, expressed as no of organisms survived; Total organisms= 52005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
AID727019Distribution coefficient, log D of the compound at pH 7.4 by HPLC-PDA analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID158369In vitro antimalarial activity against Plasmodium falciparum FCR31995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Synthesis, characterization, and antimalarial activity of the glucuronides of the hydroxylated metabolites of arteether.
AID151365Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5. 2]hexadecanes.
AID158805Blood schizonticidal activity against Plasmodium berghei NS1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID1128224Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii infected in Swiss mouse assessed as mouse survival at 24 mg/kg, po for 4 days measured on day 28 relative to control2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
New orally active amino- and hydroxy-functionalized 11-azaartemisinins and their derivatives with high order of antimalarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice.
AID158803Blood schizonticidal activity against Plasmodium berghei N/HAL1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID349093Antimalarial activity as reduced parasitaemia against multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 48 mg/kg peroral dose at day 42008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
New functionalized 1,2,4-trioxepanes: synthesis and antimalarial activity against multi-drug resistant P. yoelii in mice.
AID727018Solubility of the compound in distilled water after 24 hrs by shake flask method2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID129138Antimalarial activity was determined by blood schizonticidal activity in mice (Mus musculus) infected with Plasmodium berghei NS at 25 (mg/kgx5) peroral dosage; Cured/treated = 7/12 on day 71995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Antimalarial activity of novel ring-contracted artemisinin derivatives.
AID158800Blood schizonticidal activity against Plasmodium berghei MEN1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID272818Lipophilicity, Log P of the compound2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
New orally active derivatives of artemisinin with high efficacy against multidrug-resistant malaria in mice.
AID537166Antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis infected in Swiss mice (Mus musculus) assessed as suppression of parasitaemia at 48 mg/kg, peroral for 4 days relative to control2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Synthesis and antimalarial assessment of a new series of orally active amino-functionalized spiro 1,2,4-trioxanes.
AID730529Antimalarial activity against chloroquine-resistant Plasmodium yoelii N-67 infected in Swiss mouse assessed as reduction in parasitemia at 3 mg/kg/day, im administered for 3 days measured on day 4 relative to control2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents.
AID537170Antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis infected in Swiss mice (Mus musculus) assessed as curated mice (Mus musculus) at 48 mg/kg, peroral for 4 days2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Synthesis and antimalarial assessment of a new series of orally active amino-functionalized spiro 1,2,4-trioxanes.
AID299609Antimalarial activity as reduced parasitaemia (%) against multidrug-resistant Plasmodium yoelii infected Swiss mice (Mus musculus) at 24 mg/kg peroral dose after 4 days2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Orally active antimalarials: synthesis and bioevaluation of a new series of steroid-based 1,2,4-trioxanes against multi-drug resistant malaria in mice.
AID116771Mean survival time against Plasmodium yoelii in mice (Mus musculus) which died during 28-day observation period at 24 mg/kg/day orally2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Orally active amino functionalized antimalarial 1,2,4-trioxanes.
AID114291Antimalarial efficacy against Plasmodium berghei in mice (Mus musculus) when administered intravenously each day for 4 days to five mice (Mus musculus) per dose regimen2001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Antimalarial simplified 3-aryltrioxanes: synthesis and preclinical efficacy/toxicity testing in rodents.
AID212183Number of survivals against Plasmodium yoelii in mice (Mus musculus) (out of 5) at 24 mg/kg/day orally on day 282004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Orally active amino functionalized antimalarial 1,2,4-trioxanes.
AID537173Lipophilicity, log P of the compound2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Synthesis and antimalarial assessment of a new series of orally active amino-functionalized spiro 1,2,4-trioxanes.
AID109727Dose at which two mice demonstarted 100% survival and normal expected body weight gain after injecting with compound for 14 days2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
A short synthesis and biological evaluation of potent and nontoxic antimalarial bridged bicyclic beta-sulfonyl-endoperoxides.
AID727013Inhibition of CYP3A in rat liver microsome using testosterone as substrate by HPLC-PDA analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID129269Antimalarial activity was determined by Blood schizonticidal activity in mice (Mus musculus) infected with Plasmodium berghei K173 at 20 (mg/kg x5) peroral dosage; Cured/treated = 34/341995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Antimalarial activity of novel ring-contracted artemisinin derivatives.
AID710741Lipophilicity, log P of the compound2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Bile acid-based 1,2,4-trioxanes: synthesis and antimalarial assessment.
AID256131Prophylactic activity in infected mouse at 10 mg/kg peroral administration, expressed as no of organisms survived; Total organisms= 52005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
AID129134Antimalarial activity was determined by blood schizonticidal activity in mice (Mus musculus) infected with Plasmodium berghei NS at 5 (mg/kg x5) subcutaneous dosage; Cured/treated = 16/18 on day 71995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Antimalarial activity of novel ring-contracted artemisinin derivatives.
AID158655Blood schizonticidal activity against Plasmodium berghei MEN1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID277702Antimalarial activity against Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 48 mg/kg peroral dose over 4 days2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria.
AID710742Antimalarial activity in multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mouse assessed as suppression of parasitaemia at 24 mg/kg, po two devided dose daily for 4 days2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Bile acid-based 1,2,4-trioxanes: synthesis and antimalarial assessment.
AID256136Prophylactic activity in infected mouse at 160 mg/kg peroral administration, expressed as no of organisms survived; Total organisms= 52005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
AID129258Antimalarial activity was determined by blood schizonticidal activity in mice (Mus musculus) infected with Plasmodium berghei K173 at 1.25 (mg/kgx5) subcutaneous dosage; Cured/treated = 23/35 on day 71995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Antimalarial activity of novel ring-contracted artemisinin derivatives.
AID321286Reduced parasitemia in multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 48 mg/kg peroral dose after 4 days2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Orally active esters of dihydroartemisinin: Synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in mice.
AID730525Antimalarial activity against chloroquine-resistant Plasmodium yoelii N-67 infected in Swiss mouse assessed as mean survival time at 3 mg/kg/day, im administered for 3 days (Rvb = 9.20 +/- 0.44 days)2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents.
AID158653Blood schizonticidal activity against Plasmodium berghei ART 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID727025Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii nigeriensis infected in Swiss mouse assessed as suppression of parasitemia at 48 mg/kg, po administered for 4 days measured on day 42013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID158810Blood schizonticidal activity against Plasmodium berghei RC1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID403421Antifungal activity against Cryptococcus neoformans ATCC 90113 by modified NCCLS method2005Journal of natural products, Aug, Volume: 68, Issue:8
Antifungal activity of artemisinin derivatives.
AID661139Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as suppression of parasitemia at 6 mg/kg, im administered once daily for 4 days relative 2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID158654Blood schizonticidal activity against Plasmodium berghei B 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID129291Antimalarial activity against the chloroquine-sensitive Plasmodium falciparum NF541999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family.
AID730538Antimalarial activity against schizont stage of chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by SYBR Green I-based fluorescence assay2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents.
AID158520In vitro antimalarial activity against drug-resistant Plasmodium falciparum W-21995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and antimalarial activities of 12 beta-allyldeoxoartemisinin and its derivatives.
AID158662Blood schizonticidal activity against Plasmodium berghei PYR 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID727010Half life in rat liver microsomes at 1 mM by HPLC-PDA analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID324894Antimalarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice (Mus musculus) as reduced parasitaemia after peroral 48 mg/kg dose for 4 days2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Orally active 1,2,4-trioxepanes: synthesis and antimalarial activity of a series of 7-arylvinyl-1,2,4-trioxepanes against multidrug-resistant Plasmodium yoelii in Swiss mice.
AID130256In vivo antimalarial activity against Plasmodium berghei N on subcutaneous administration.1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family.
AID158372In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum K12004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Antimalarial activities of (+)-deoxoartemisitene and its novel C-11, 13 derivatives.
AID158856Inhibitory concentration against Plasmodium falciparum W2 Indochina1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID158802Blood schizonticidal activity against Plasmodium berghei N/11001988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID158685In vitro inhibitory activity against Plasmodium falciparum (sierra leone clone)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID224679Evaluated for the survival of the mice when 64 mg/kg/day was administered subcutaneously to Plasmodium berghei infected mice on days 3, 4, and 5 post infection; 7/C(C=survival beyond 60 days)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5. 2]hexadecanes.
AID537167Antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis infected in Swiss mice (Mus musculus) assessed as suppression of parasitaemia at 24 mg/kg, peroral for 4 days relative to control2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Synthesis and antimalarial assessment of a new series of orally active amino-functionalized spiro 1,2,4-trioxanes.
AID727011Intrinsic clearance in rat liver microsomes at 1 mM by HPLC-PDA analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID119887In vivo antimalarial activity against Plasmodium yoelii in mice (Mus musculus) at 48 mg/kg/day orally on day 4 expressed as percent suppression2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Orally active amino functionalized antimalarial 1,2,4-trioxanes.
AID225006In vivo antimalarial activity against Plasmodium chabaudi in mice (Mus musculus) and its survival rate reported2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid.
AID403420Antifungal activity against Candida albicans ATCC 90028 by modified NCCLS method2005Journal of natural products, Aug, Volume: 68, Issue:8
Antifungal activity of artemisinin derivatives.
AID264200Antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in mice (Mus musculus) at 48 mg/kg/day peroral dose over 4 days2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.
AID338835Cytotoxicity against mouse EAC after 3 days by MTT assay1993Journal of natural products, Jun, Volume: 56, Issue:6
Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells.
AID661145Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as disease cured mouse at 3 mg/kg, im administered once daily for 4 days measured on day 2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID132765In vivo antimalarial activity against Plasmodium berghei N on subcutaneous administration.1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family.
AID730537Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 after 72 hrs by SYBR Green I-based fluorescence assay2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents.
AID158400In vitro antimalarial activity against drug-resistant Plasmodium falciparum D61995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and antimalarial activities of 12 beta-allyldeoxoartemisinin and its derivatives.
AID129267Antimalarial activity was determined by Blood schizonticidal activity in mice (Mus musculus) infected with Plasmodium berghei K173 at 2.5 (mg/kgx5) subcutaneous dosage; Cured/treated = 36/361995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Antimalarial activity of novel ring-contracted artemisinin derivatives.
AID224853Evaluated for the percentage of subcutaneously to Plasmodium berghei infected mice on days 3, 4, and 5 post infection.2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5. 2]hexadecanes.
AID112564In vivo antimalarial activity in mice (Mus musculus) against chloroquine-sensitive Plasmodium berghei N after subcutaneous administration2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
A short synthesis and biological evaluation of potent and nontoxic antimalarial bridged bicyclic beta-sulfonyl-endoperoxides.
AID158661Blood schizonticidal activity against Plasmodium berghei P 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID28256Half life was reported2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid.
AID158656Blood schizonticidal activity against Plasmodium berghei N 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID159625In vitro inhibitory activity against chloroquine-sensitive Plasmodium falciparum African D62002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Mixed steroidal 1,2,4,5-tetraoxanes: antimalarial and antimycobacterial activity.
AID730536Resistance ratio of IC5O for Plasmodium falciparum K1 to IC50 for Plasmodium falciparum 3D72013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents.
AID422752Antimalarial activity as reduced parasitaemia at day 10 against Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) at 10 mg/kg/day intraperitoneal dose for 3 days2009Journal of natural products, Jan, Volume: 72, Issue:1
Indolizidine, antiinfective and antiparasitic compounds from Prosopis glandulosa var. glandulosa.
AID212184Number of survivals against Plasmodium yoelii in mice (Mus musculus) (out of 5) at 48 mg/kg/day orally on day 282004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Orally active amino functionalized antimalarial 1,2,4-trioxanes.
AID272814Antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 48 mg/kg peroral dose over 4 days2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
New orally active derivatives of artemisinin with high efficacy against multidrug-resistant malaria in mice.
AID158807Blood schizonticidal activity against Plasmodium berghei P1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID422758Antimalarial activity as elimination of parasitaemia at day 28 against Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) at 10 mg/kg/day intraperitoneal dose for 3 days2009Journal of natural products, Jan, Volume: 72, Issue:1
Indolizidine, antiinfective and antiparasitic compounds from Prosopis glandulosa var. glandulosa.
AID730534Selectivity index, ratio of CC50 for african green monkey Vero C1008 cells to IC50 for Plasmodium falciparum K12013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents.
AID730535Cytotoxicity against african green monkey Vero C1008 cells after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents.
AID158855Inhibitory concentration against Plasmodium falciparum D6 (Sierra Leone)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID158373In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D72004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Antimalarial activities of (+)-deoxoartemisitene and its novel C-11, 13 derivatives.
AID727024Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii nigeriensis infected in Swiss mouse assessed as suppression of parasitemia at 24 mg/kg, po administered for 4 days measured on day 42013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID158663Blood schizonticidal activity against Plasmodium berghei QS1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID272819Protection of Swiss mice (Mus musculus) infected with Plasmodium yoelii nigeriensis at 48 mg/kg, perorally for 4 days2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
New orally active derivatives of artemisinin with high efficacy against multidrug-resistant malaria in mice.
AID158804Blood schizonticidal activity against Plasmodium berghei NPN1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID158799Blood schizonticidal activity against Plasmodium berghei B1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID158658Blood schizonticidal activity against Plasmodium berghei NPN 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID158652Blood schizonticidal activity against Plasmodium berghei 1100 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID383806Cytotoxicity against mouse Ehrlich Ascites carcinoma by trypan blue exclusion assay2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Bioactive peroxides as potential therapeutic agents.
AID112549Antimalarial efficacy against Plasmodium berghei in mice (Mus musculus) when administered subcutaneously each day for 4 days to five mice (Mus musculus) per dose regimen2001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Antimalarial simplified 3-aryltrioxanes: synthesis and preclinical efficacy/toxicity testing in rodents.
AID661140Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as suppression of parasitemia at 3 mg/kg, im administered once daily for 4 days relative 2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID727021Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii nigeriensis infected in Swiss mouse assessed as protection against parasite-induced mortality at 24 mg/kg, po administered for 4 days measured on day 282013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID493712Antimalarial activity against multi drug-resistant Plasmodium yoelii nigeriensis infected in Swiss mice (Mus musculus) assessed as suppression of parasitaemia level at 48 mg/kg, perorally daily for 4 days2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
6-(4'-Aryloxy-phenyl)vinyl-1,2,4-trioxanes: a new series of orally active peroxides effective against multidrug-resistant Plasmodium yoelii in Swiss mice.
AID1128223Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii infected in Swiss mouse assessed as suppression of parasitemia at 48 mg/kg, po for 4 days by microscopic analysis relative to control2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
New orally active amino- and hydroxy-functionalized 11-azaartemisinins and their derivatives with high order of antimalarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice.
AID116772Mean survival time against Plasmodium yoelii in mice (Mus musculus) which died during 28-day observation period at 48 mg/kg/day orally2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Orally active amino functionalized antimalarial 1,2,4-trioxanes.
AID661144Antimalarial activity against chloroquine-, mefloquine-, halofantrine-resistant Plasmodium yoelii nigeriensis blood stream schizonts infected in Swiss mouse assessed as disease cured mouse at 6 mg/kg, im administered once daily for 4 days measured on day 2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
AID158527In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 (Indochina)1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID349096Antimalarial activity as survivor numbers against multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 48 mg/kg peroral dose at day 282008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
New functionalized 1,2,4-trioxepanes: synthesis and antimalarial activity against multi-drug resistant P. yoelii in mice.
AID710738Antimalarial activity in multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mouse assessed as disease cure at 24 mg/kg, po two devided dose daily for 4 days by 28 day survival assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Bile acid-based 1,2,4-trioxanes: synthesis and antimalarial assessment.
AID264201Antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in mice (Mus musculus) at 24 mg/kg/day peroral dose after 4 days2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.
AID727022Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii nigeriensis infected in Swiss mouse assessed as protection against parasite-induced mortality at 48 mg/kg, po administered for 4 days measured on day 282013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID225003In vivo antimalarial activity against Plasmodium chabaudi in mice (Mus musculus) and its survival was reported2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid.
AID158526In vitro antimalarial activity against mefloquine-resistant Plasmodium falciparum D6 (Sierra Leone)1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and antimalarial activity of (+)-deoxoartemisinin.
AID727014Inhibition of CYP2D4 in rat liver microsome using dextromethorphan as substrate by HPLC-PDA analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID158657Blood schizonticidal activity against Plasmodium berghei N/HAL 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID299611Survival of multidrug-resistant Plasmodium yoelii infected Swiss mice (Mus musculus) at 48 mg/kg, perorally after 28 days2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Orally active antimalarials: synthesis and bioevaluation of a new series of steroid-based 1,2,4-trioxanes against multi-drug resistant malaria in mice.
AID114292Antimalarial efficacy against Plasmodium berghei in mice (Mus musculus) when administered subcutaneously each day for 4 days to five mice (Mus musculus) per dose regimen2001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Antimalarial simplified 3-aryltrioxanes: synthesis and preclinical efficacy/toxicity testing in rodents.
AID157679In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum K12002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid.
AID727009Inhibition of CYP2C11 in rat liver microsome using diclofenac as substrate by HPLC-PDA analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID151363Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5. 2]hexadecanes.
AID159766In vitro inhibitory activity against chloroquine-resistant Plasmodium falciparum W2 Indochina2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Mixed steroidal 1,2,4,5-tetraoxanes: antimalarial and antimycobacterial activity.
AID299608Antimalarial activity as reduced parasitaemia (%) against multidrug-resistant Plasmodium yoelii infected Swiss mice (Mus musculus) at 48 mg/kg peroral dose after 4 days2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Orally active antimalarials: synthesis and bioevaluation of a new series of steroid-based 1,2,4-trioxanes against multi-drug resistant malaria in mice.
AID727016Metabolic stability in rat liver microsomes at 1 mM after 30 mins by HPLC-PDA analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID493713Antimalarial activity against multi drug-resistant Plasmodium yoelii nigeriensis infected in Swiss mice (Mus musculus) assessed as suppression of parasitaemia level at 24 mg/kg, perorally daily for 4 days2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
6-(4'-Aryloxy-phenyl)vinyl-1,2,4-trioxanes: a new series of orally active peroxides effective against multidrug-resistant Plasmodium yoelii in Swiss mice.
AID710739Antimalarial activity in multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mouse assessed as disease cure at 48 mg/kg, po two devided dose daily for 4 days by 28 day survival assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Bile acid-based 1,2,4-trioxanes: synthesis and antimalarial assessment.
AID422755Antimalarial activity as reduced parasitaemia at day 17 against Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) at 10 mg/kg/day intraperitoneal dose for 3 days2009Journal of natural products, Jan, Volume: 72, Issue:1
Indolizidine, antiinfective and antiparasitic compounds from Prosopis glandulosa var. glandulosa.
AID1128220Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii infected in Swiss mouse assessed as suppression of parasitemia at 24 mg/kg, po for 4 days by microscopic analysis relative to control2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
New orally active amino- and hydroxy-functionalized 11-azaartemisinins and their derivatives with high order of antimalarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice.
AID158660Blood schizonticidal activity against Plasmodium berghei ORA 1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID321289Partition coefficient, log P of the compound2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Orally active esters of dihydroartemisinin: Synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in mice.
AID113170In vivo antimalarial activity in mice (Mus musculus) against chloroquine-sensitive Plasmodium berghei N after subcutaneous administration2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
A short synthesis and biological evaluation of potent and nontoxic antimalarial bridged bicyclic beta-sulfonyl-endoperoxides.
AID277704Antimalarial activity against Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 24 mg/kg peroral dose over 4 days2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria.
AID727012Inhibition of CYP1A2 in rat liver microsome using phenacetin as substrate by HPLC-PDA analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID84804Inhibitory activity against human umbilical vein endothelial cells (HUVEC) was assayed using MTT colorimetric proliferation assay2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
Growth inhibition activity of thioacetal artemisinin derivatives against human umbilical vein endothelial cells.
AID727015Fraction unbound in rat plasma at 10 uM by ultra-filtration method2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.
AID277706Survival of Swiss mice (Mus musculus) infected with Plasmodium yoelii nigeriensis at 48 mg/kg, peroral after 28 days2007Journal of medicinal chemistry, Feb-08, Volume: 50, Issue:3
New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria.
AID158809Blood schizonticidal activity against Plasmodium berghei QS1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID321287Antimalarial activity as reduced parasitemia day 4 against multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 24 mg/kg/day peroral dose over 4 days2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Orally active esters of dihydroartemisinin: Synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in mice.
AID730533Selectivity index, ratio of CC50 for african green monkey Vero C1008 cells to IC50 for Plasmodium falciparum 3D72013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents.
AID262123Antiangiogenic activity at chorioallantoic membrane of chick embryo at 5 nmol per egg2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane.
AID158801Blood schizonticidal activity against Plasmodium berghei N1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID158806Blood schizonticidal activity against Plasmodium berghei ORA1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID1128227Antimalarial activity against chloroquine, mefloquine and halofantrine-resistant Plasmodium yoelii infected in Swiss mouse assessed as mouse survival at 48 mg/kg, po for 4 days measured on day 28 relative to control2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
New orally active amino- and hydroxy-functionalized 11-azaartemisinins and their derivatives with high order of antimalarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice.
AID224678Evaluated for the survival of the mice when 128 mg/kg/day was administered orally to Plasmodium berghei infected mice on days 3, 4, and 5 post infection; 5/C(C=survival beyond 60 days)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5. 2]hexadecanes.
AID338840Cell cycle arrest in mouse EAC assessed as accumulation at S phase by FACS analysis1993Journal of natural products, Jun, Volume: 56, Issue:6
Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells.
AID710743Antimalarial activity in multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mouse assessed as suppression of parasitaemia at 48 mg/kg, po two devided dose daily for 4 days2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Bile acid-based 1,2,4-trioxanes: synthesis and antimalarial assessment.
AID158863Intrinsic equimolar activity against Plasmodium falciparum W2 Indochina relative to QHS1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID158659Blood schizonticidal activity against Plasmodium berghei NS1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID272815Antimalarial activity as cures against multidrug-resistant Plasmodium yoelii nigeriensis infected Swiss mice (Mus musculus) at 48 mg/kg peroral dose over 4 days2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
New orally active derivatives of artemisinin with high efficacy against multidrug-resistant malaria in mice.
AID158862Intrinsic equimolar activity against Plasmodium falciparum D6 (Sierra Leone) relative to QHS1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID158808Blood schizonticidal activity against Plasmodium berghei PYR1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID1546461Antitumour activity against mouse mammary cancer cells transplanted in Balb/c mouse assessed as tumour size at 6 mg/kg, ip for 13 days2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (185)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (3.78)18.7374
1990's56 (30.27)18.2507
2000's63 (34.05)29.6817
2010's48 (25.95)24.3611
2020's11 (5.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.70 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (8.47%)5.53%
Trials0 (0.00%)5.53%
Reviews14 (7.41%)6.00%
Reviews0 (0.00%)6.00%
Case Studies1 (0.53%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other158 (83.60%)84.16%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]